Want to see RNTX full AI Analyst Report?
RNTX Stock Chart & Stats
$1.26
--
Market closed
$1.26
--
Day’s Range― - ―
52-Week Range$0.73 - $2.18
Previous CloseN/A
VolumeN/A
Average Volume (3M)228.95K
Market Cap
$65.69M
Enterprise Value$84.94
Total Cash (Recent Filing)$4.45M
Total Debt (Recent Filing)$4.92M
Price to Earnings (P/E)―
Beta1.24
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding85,539,030
10 Day Avg. Volume262,542
30 Day Avg. Volume228,948
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside376.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ProgressOpening the randomized, placebo-controlled Phase 2 RENEW across five countries materially strengthens the company's ability to recruit ~120 IPF patients. Broader geography reduces site-specific enrollment risk and supports timely readouts, improving execution certainty for the LTI-03 program over the next 2–6 months.
Funding RunwayThe $50M underwritten offering materially extends the clinical and corporate runway, explicitly funding the ongoing Phase 2 trial and operations into 2028. This reduces immediate refinancing pressure and enables focus on clinical milestones rather than emergency fundraising over the medium term.
Modest LeverageRelatively low reported debt provides financial flexibility and limits interest expense burden while the company runs clinical programs. Modest leverage makes debt financing less likely and preserves optionality for non-dilutive capital sources, supporting stability during development stages.
Bears Say
No Revenue & Cash BurnThe company is a clinical-stage biotech with no product revenue and sustained negative operating and free cash flow. Continued net losses and cash burn require recurring financing to sustain trials, creating structural funding dependency and execution risk if capital access deteriorates over the next several quarters.
Dilution RiskDoubling authorized shares plus the sizable public offering increases the potential for future dilution and signals reliance on equity financing. Expanded share capacity and recent issuance mechanics can compress existing ownership and reduce per-share upside for current investors if additional raises are required.
Shrinking Equity BaseA sharp decline in stockholders' equity and deeply negative return on equity reflect accumulated losses and capital changes. A diminished equity buffer raises solvency risk, limits balance-sheet resilience to adverse trial outcomes, and increases the likelihood of future dilutive financings.
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $0.72 and its highest was $2.18 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $65.69M.
When is Rein Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rein Therapeutics’s earnings last quarter?
Currently, no data Available
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 85,539,030 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (376.19% Upside)
$6.00 (376.19% Upside)
Insider Transactions
Bought Shares
Worth $74.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-54.38%
Trailing 12-Months
Company Description
Rein Therapeutics
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
RNTX Stock 12 Month Forecast
Average Price Target
$6.00
▲(376.19% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Cardiff Oncology
―
XBiotech
―
Elicio Therapeutics
―
Xilio Therapeutics
―
Ownership Overview
1.77% Insiders
1.38% Mutual Funds
11.00% Other Institutional Investors
81.78% Public Companies and
Individual Investors